4 results
To determine the toxicity of adding chloroquine in escalating doses in patients with small cell lung cancer to standard therapy.
To determine the toxicity of adding chloroquine in escalating doses in patients with small cell lung cancer to standard therapy.
Primary: To assess the proportion of patients with intervention failure at 12 months after dose reduction, defined as patients who have restarted their initial dose due to (expected) loss of major molecular response.
- To assess the effect of food (high-fat) on the bioavailability and pharmacokinetic (PK)- profile of a solid dosage formulation of JNJ-67953964.- To assess the effects of repeated QD administration of 200 mg of itraconazole (steady state) on the…